Related Experiment Video
Updated: Apr 15, 2026
12:18
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
8.2K
Statins, cognition, and dementia—systematic review and methodological commentary
Melinda C Power1, Jennifer Weuve2, A Richey Sharrett1
1Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 North Wolfe Street, Baltimore, MD 21205, USA.
Nature Reviews. Neurology
|March 25, 2015
Summary
Long-term statin use does not prevent cognitive decline or dementia. While some studies suggest a benefit, these findings may be due to biases like reverse causation, not a true protective effect.
Area of Science:
- Neurology
- Pharmacology
- Epidemiology
Background:
- The relationship between statin use and cognitive decline remains unclear.
- Existing research presents conflicting evidence regarding statins' impact on dementia risk.
Purpose of the Study:
- To systematically review and synthesize epidemiological literature on statin use and cognition.
- To assess current knowledge, identify research gaps, and recommend future study designs.
Main Methods:
- Comprehensive review of randomized controlled trials (RCTs) and observational studies.
- Analysis of study designs, potential biases (e.g., reverse causation, confounding), and follow-up periods.
Main Results:
- Observational studies near dementia diagnosis suggest statin protection, potentially due to reverse causation.
- RCTs and well-designed observational studies of early statin use show no preventative effect on cognitive decline or dementia.
Conclusions:
- Current evidence does not support a causal link between late-life statin use and prevention of cognitive decline or dementia.
- Future observational research requires rigorous design and analysis to mitigate bias and clarify statins' role in cognitive health.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.9K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.9K
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
356
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
356
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
914
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
914
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:26Atherosclerosis III: Management
605
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
605
01:30Dementia
728
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
728